Coherus Acquires Bevacizumab Rights From Innovent
Deal Also Includes Option To Sell Innovent’s Rituximab Biosimilar
Coherus BioSciences has struck a deal with China’s Innovent Biologics that gives it US and Canadian rights to a bevacizumab biosimilar version of Avastin as well as an option to market Innovent’s rituximab rival to Rituxan in the US and Canada.
You may also be interested in...
Innovent and marketing partner Etana have celebrated an approval for their Bevagen bevacizumab biosimilar from the Indonesian regulator.
Coherus BioSciences, juggling both biosimilar and novel biologic assets, has called time on its partnership with China’s Innovent Biologics for biosimilar Avastin – a year after shelving development of biosimilar Eylea.
Apotex has received Health Canada approval for its Bambevi bevacizumab rival to Avastin, with the firm citing the nod as a first for its Apobiologix division.